Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Biomarkers of disease

With investigations of phytochemicals and functional foods, the outcome measure is generally going to be a biomarker of disease, such as serum cholesterol level as a marker of heart disease risk, or indicators of bone turnover as markers of osteoporosis risk. Alternatively, markers of exposure may also indicate the benefit from a functional food by demonstrating bioavailability, such as increased serum levels of vitamins or carotenoids. Some components will be measurable in both ways. For instance, effects of a folic acid-fortified food could be measured via decrease in plasma homocysteine levels, or increase in red blood cell folate. [Pg.240]

Liao, H., Wu, J., Kuhn, E., Chin, W, Chang, B., Jones, M.D., O Neil, S., Clauser, K.R., Karl, J., Hasler, F., Roubenoff, R., Zolg, W. and Guild, B.C. (2004) Use of Mass Spectrometry to Identify Protein Biomarkers of Disease Severity in the Synovial Fluid and Serum of Patients with Rheumatoid Arthritis. Arthritis Rheum, 50, 3792-3803. [Pg.82]

Biomarkers of Disease. No disease states in humans produced by exposure to isophorone are known. If epidemiological studies are conducted that correlate exposure with diseases, it may be possible to identify subtle changes associated with a particular disease state. [Pg.64]

Biomarkers of Disease. No biomarkers are known that are specific for BCME-induced lung injury. Standard chemical examination of nose and throat can provide an index of local irritation, and examination of sputum for abnormal cell types can provide information on the state of the respiratory epithelium. However, these tests cannot distinguish BCME-induced effects from effects caused by smoking or exposure to other chemicals, and can only discover changes after damage to the tissue has already occurred. Continued efforts to devise more sensitive and more specific early biomarkers of disease (especially lung cancer) would be valuable. [Pg.41]

Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Verhulst SJ. CSF B-cell expansion in opsoclonus-myoclonus syndrome A biomarker of disease activity. Mov Disord 2004 19(7) 770-777. [Pg.176]

The focus of proteomics has turned to identifying potential biomarkers of disease. A biomarker, by definition, is (a) a molecular indicator for a specific biological property or (b) a feature or facet that can be used to measure the progress of disease or the effects of treatment. As an example, a biomarker... [Pg.537]

Liao H, et al. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum. 2004 50 3792-3803. [Pg.1812]

Simpson EP, Henry YK, Henkel JS, Smith RG, Appel SH (2004) Increased lipid peroxidation in sera of ALS patients A potential biomarker of disease burden. Neurology 62 1758-1765. [Pg.387]

Enzyme immunoassay is widely used, both in competitive and non-competitive formats, for the bioanalysis of a broad range of low-molecular-weight compounds and macromolecules. Through the use of fluorogenic substrates and amplification systems such as avidin-biotin, the sensitivity of enzyme immunoassay has been developed to equal or exceed that of radioimmunoas-say.f ° The technique has found particularly wide applicability in the determination of new recombinant proteins, in demonstrating antibody responses to macromolecules, and in the measurement of biomarkers of disease, as well as in diagnostic medicine. [Pg.1578]

The expression level of proteins in cells is constantly in flux owing to changes in biochemical pathways. Differential expression of proteins is also the result of different physiological states (e.g., healthy versus diseased subjects) or stress due to external stimuli (e.g., by drugs or toxins). These changes can be monitored through differential proteomics also called quantitative proteomics.43 The task involves identification of proteins and comparison of their expression level in control versus test samples. This subfield of proteomics has also opened the avenues to discover biomarkers of diseases and opportunities for early diagnostic intervention and prevention of diseases. Protein—protein interactions can also be explored with quantitative proteomics. [Pg.467]

Biomarkers of Disease. Since acute NDMA poisoning in humans caused severe liver disease, sensitive clinical biochemistry liver function tests might detect early hepatic damage from toxic exposure to NDMA. Recently,... [Pg.68]

Biomarkers of Disease. No studies were located that identified biomarkers specific for... [Pg.56]

Why is it important to accept this challenge A current and near future priority of biomedical research is to understand and treat complex diseases like diabetes, heart disease, and cancer that have only recently become prevalent sources of morbidity and mortality in human populations. A major goal of systems biology and proteomics is to identify and quantify specific proteins for use as predictive diagnostic and/or prognostic biomarkers of disease [32]. Biomarker discovery is... [Pg.78]


See other pages where Biomarkers of disease is mentioned: [Pg.18]    [Pg.40]    [Pg.44]    [Pg.49]    [Pg.39]    [Pg.40]    [Pg.46]    [Pg.282]    [Pg.614]    [Pg.303]    [Pg.102]    [Pg.1052]    [Pg.459]    [Pg.299]    [Pg.304]    [Pg.320]    [Pg.412]    [Pg.141]    [Pg.6]    [Pg.9]    [Pg.268]    [Pg.512]    [Pg.105]    [Pg.242]    [Pg.38]    [Pg.218]    [Pg.79]    [Pg.98]    [Pg.51]    [Pg.1395]    [Pg.303]    [Pg.514]    [Pg.515]    [Pg.412]   
See also in sourсe #XX -- [ Pg.314 , Pg.514 , Pg.515 ]




SEARCH



Biomarkers disease

© 2024 chempedia.info